Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Emapalumab × 90 days × Clear all
NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡